Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Interest Expenses (2019 - 2025)

Historic Interest Expenses for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to $11.7 million.

  • BridgeBio Pharma's Interest Expenses fell 4909.59% to $11.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.3 million, marking a year-over-year increase of 3521.51%. This contributed to the annual value of $99.3 million for FY2024, which is 2214.44% up from last year.
  • Per BridgeBio Pharma's latest filing, its Interest Expenses stood at $11.7 million for Q3 2025, which was down 4909.59% from $37.6 million recorded in Q2 2025.
  • BridgeBio Pharma's 5-year Interest Expenses high stood at $42.1 million for Q1 2025, and its period low was $9.7 million during Q1 2021.
  • Moreover, its 5-year median value for Interest Expenses was $20.3 million (2022), whereas its average is $21.0 million.
  • In the last 5 years, BridgeBio Pharma's Interest Expenses surged by 14284.29% in 2021 and then plummeted by 4909.59% in 2025.
  • Over the past 5 years, BridgeBio Pharma's Interest Expenses (Quarter) stood at $15.1 million in 2021, then skyrocketed by 32.09% to $20.0 million in 2022, then grew by 1.39% to $20.3 million in 2023, then surged by 47.13% to $29.8 million in 2024, then tumbled by 60.64% to $11.7 million in 2025.
  • Its last three reported values are $11.7 million in Q3 2025, $37.6 million for Q2 2025, and $42.1 million during Q1 2025.